Scholar Rock reports FY2022 net loss of $134.5M; revenue up to $33.2M; apitegromab Phase 3 enrollment on track for 2023

Scholar Rock Holding Corp

Net loss of $134.5M ($2.26 per share) in FY2022; revenue $33.2M vs $18.8M prior year.
Cash, cash equivalents, and marketable securities of $315M; expects to fund ops into 2025.
Phase 3 SAPPHIRE trial enrollment of apitegromab on track to complete in 2023; top-line data expected 2024.
36-month extension data from Phase 2 TOPAZ trial expected in mid-2023; ~90% of patients remained on study.
Appointed Tracey M. Sacco as Chief Commercial Officer in Feb 2023 to lead launch preparation for apitegromab.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Scholar Rock Holding Corp reported the full year ended December 31, 2022 results: revenue $33.2 million, net income net loss was $134.5 million, EPS $2.26 per share.

Period: the full year ended December 31, 2022
Revenue: $33.2 million
Net income: net loss was $134.5 million
EPS: $2.26 per share
Result: reported results

Exact text from the filing

For the full year ended December 31, 2022, net loss was $134.5 million or $2.26 per share compared to a net loss of $131.8 million or $3.59 per share for the full year ended December 31, 2021. Revenue was $33.2 million for the year ended December 31, 2022, compared to $18.8 million for the year ended December 31, 2021.

View on SEC.gov

Browse all earnings releases →

Scholar Rock Holding Corp filing history →

Source: SEC EDGAR

accession 0001157523-23-000400

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.